US Market-Entry Masterclass - FDA Regulatory Roadmap is an online masterclass aimed at medical device and life science product companies seeking to expand into the U.S. market. This 90-minute session, organised by GTM Global in association with QRx Partners, will provide crucial guidance on navigating the complex U.S. regulatory landscape, especially FDA requirements.
Job type: 2-year fixed term contract
Location: Oxford
Salary: Competitive salary
Right to work: You must have the right to work in the UK
Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab)
Cambridge, UK – 7 October 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its advanced melanoma (MELODY-1) trial. This international trial is due to recruit up to 40 patients at clinical centres in the UK, France, Italy and Spain. Initial data readouts are expected by the end of 2025.
Dr Gordon McInroy appointed as COO, Dr Tobias Ost as SVP Product Development, and Charu Maini as SVP of People
Pioneer Group has announced its successful exit from Alderley Analytical, a leading independent contract research organisation (CRO) specialising in bioanalytical services, following the company’s acquisition by Synexa Life Sciences Ltd, a Dutch-based company backed by major European healthcare investor Gilde Healthcare.
Ingenza, a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator, has signed a 10-year lease at the Moubray Building at Edinburgh Technopole, part of Pioneer Group.
Following a detailed strategic review, the company has embarked on the creation of a multi-million-pound facility to help drive its ambitious growth plans. The purpose-built premises will more than double the company’s current footprint to approximately 25,000 sq ft, expanding its fermentation and research facilities.
London, October 3, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and the Nitinotes Board to conduct a successful search for a new Chief Executive Officer (“CEO”) for Nitinotes. We are pleased to announce the placement of Lloyd Diamond in this key leadership role.
Cancer Research UK, one of the world’s largest funders of cancer research, and NovalGen, a pioneering clinical stage immunology company, have signed an agreement to bring NovalGen’s next-generation T-cell engager, NVG-222, into a first-in-human clinical trial.
📖 Read October's eNews here 👉 https://shorturl.at/CUF5k
Featuring:
✅ Tony Jones, CEO, One Nucleus: Engaging Our Members and Their Peers
✅ Navigate Your Opportunities with Ease - Introducing the New Look One Nucleus Website
✅ How Can You Stay One Step Ahead in the Ever More Competitive Drug Discovery Space? by Domainex